Evidence map›Paper›PMID 37090662›Full record

ArticleResearch square2023

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.

In Young Choi, Jonathan Ling, Jian Zhang, Eric Helmenstine, Wencke Walter, Riley Bergman, Céline Philippe, James Manley, Kevin Rouault-Pierre, Bing Li and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 4 countries.

In Young ChoiJohns Hopkins University School of Medicine.
Jonathan LingJohns Hopkins University.
Jian ZhangColumbia University.ORCID 0000-0001-7565-1471
Eric HelmenstineJohns Hopkins University.
Wencke WalterMLL Münchner Leukämielabor GmbH.ORCID 0000-0002-5083-9838
Riley BergmanVanderbilt University.
Céline PhilippeBarts Cancer Institute, Queen Mary University of London.ORCID 0000-0002-8546-3893
James ManleyColumbia University.
Kevin Rouault-PierreBarts Cancer Institute - Queen Mary University of London.ORCID 0000-0001-7671-7364
Bing LiInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Daniel WisemanThe University of Manchester.ORCID 0000-0003-0715-1402
Madhu OusephWeill Cornell Medical College.
Elsa BernardMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-2057-7187
Xiao LiShanghai Jiao Tong University Affiliated Sixth People's Hospital.
Torsten HaferlachMLL Munich Leukemia Laboratory.
Salman FazalAllegheny Health Network.
Tania JainSidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.ORCID 0000-0001-6854-773X
Christopher GockeJohns Hopkins University School of Medicine.ORCID 0000-0002-9541-2192
Amy DeZernJohns Hopkins University School of Medicine.ORCID 0000-0001-5225-4609
W Brian DaltonJohns Hopkins Medicine.
Johns Hopkins University · USColumbia University · USMunich Leukemia Laboratory (Germany) · DEQueen Mary University of London · GBAllegheny Health Network · USChinese Academy of Medical Sciences & Peking Union Medical College · CNCornell University · USMemorial Sloan Kettering Cancer Center · USShanghai Jiao Tong University · CNUniversity of Manchester · GBVanderbilt University Medical Center · US

Funding

Regulation of RNA processing: Mechanisms and ConsequencesR35GM118136 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI James L. Manley · 2016 to 2026
$8.9M
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDSR01HL159306 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DALTON, WILLIAM BRIAN, DEZERN, AMY E · 2022 to 2025
$1.6M
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDSR56HL159306 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DALTON, WILLIAM BRIAN, DEZERN, AMY E · 2021 to 2021
$409k
Harnessing hotspot specific differences among SF3B1 mutations to define novel mechanisms of tumorigenicity and targetability in solid malignanciesF30CA268325 · NCI · VANDERBILT UNIVERSITY · PI BERGMAN, RILEY · 2023 to 2025
$141k
NCI NIH HHS F30 CA268325NHLBI NIH HHS R01 HL159306NHLBI NIH HHS R56 HL159306NIGMS NIH HHS R35 GM118136
6 · The paper itself

Abstract

Among the most common genetic alterations in the myelodysplastic syndromes (MDS) are mutations in the spliceosome gene

Identifiers

PMID37090662
PMCPMC10120771
OpenAlexW4365509745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.